Trial of IFN or STI571 before proceeding to allografting for CML?

• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Titel: Trial of IFN or STI571 before proceeding to allografting for CML?
• Verf.angabe: R. Hehlmann
• E-Jahr: 2000
• Jahr: 31 August 2000
• Umfang: 3 S.
• Fussnoten: Gesehen am 19.05.2022
• Titel Quelle: Enthalten in: Leukemia
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2000
• Band/Heft Quelle: 14(2000), 9, Seite 1560-1562
• ISSN Quelle: 1476-5551
• DOI: doi:10.1038/sj.leu.2401874
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cancer Research
• Sach-SW: general
• Sach-SW: Hematology
• Sach-SW: Intensive / Critical Care Medicine
• Sach-SW: Internal Medicine
• Sach-SW: Medicine/Public Health
• Sach-SW: Oncology
• K10plus-PPN: 1802593225

Abstract

Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantification of survival after BMT and IFN treatment suggests that a trial of IFN (and possibly STI 571) before proceeding to allografting is a viable, and in low risk patients a probably preferable option.